Key Takeaways
- Gilead Sciences has reached an agreement to purchase Germany’s Tubulis GmbH in a transaction valued at up to $5 billion, including a $3.15 billion initial payment.
- The acquisition strengthens Gilead’s antibody-drug conjugate (ADC) portfolio, with candidates targeting ovarian and non-small cell lung cancers.
- RBC Capital Markets increased its GILD price target from $118 to $123 while maintaining a Sector Perform rating.
- RBC projects Yeztugo could surpass Q1 estimates by approximately $180 million, though warns of potential headwinds from compliance rates and market penetration challenges.
- Multiple analysts including Cantor Fitzgerald, UBS, and Deutsche Bank maintain bullish ratings with price targets reaching $155.
Gilead Sciences (GILD) is strengthening its oncology division through a strategic acquisition of Tubulis GmbH, a Munich-based biotechnology company, in an all-cash transaction worth up to $5 billion.
The pharmaceutical giant will pay $3.15 billion immediately, with an additional $1.85 billion contingent on achieving specific developmental and commercial milestones. Financing will come from existing cash reserves and newly issued senior unsecured notes, with the transaction anticipated to finalize in the second quarter of 2026.
Tubulis specializes in developing antibody-drug conjugates—innovative cancer therapies that deliver chemotherapy agents directly to malignant cells while minimizing damage to healthy tissue. The company’s primary candidate, TUB-040, is currently undergoing Phase 1b/2 clinical evaluation for platinum-resistant ovarian cancer and non-small cell lung cancer treatment.
Chief Executive Daniel O’Day characterized the expanded pipeline as potentially representing the most robust and varied portfolio in Gilead’s corporate history.
Shares declined approximately 1.37% following Tuesday’s announcement, a common market response when companies commit substantial upfront capital to acquisitions.
RBC Increases Valuation While Maintaining Cautious Outlook
RBC Capital Markets adjusted its GILD price objective upward to $123 from the previous $118, while retaining its Sector Perform designation—effectively a neutral recommendation. The investment firm highlighted encouraging early performance data for Yeztugo, one of Gilead’s recent launches, based on third-party prescription tracking.
RBC’s analysis suggests Yeztugo might exceed first-quarter consensus forecasts by approximately $180 million, significantly above the $141 million Street estimate. This would represent a substantial outperformance if realized.
However, RBC expressed measured concerns about forward projections. The firm observed that buy-side expectations for full-year 2026 may already incorporate roughly $1 billion in Yeztugo revenue. Should patient adherence rates or market penetration fall short of expectations, these optimistic peak revenue projections could face downward revisions.
Current compliance metrics hover around 70% according to RBC’s proprietary research—a respectable figure, but one offering limited cushion for deterioration.
RBC also identified potential weakness in other divisions. The firm’s HIV revenue estimate stands at $4.8 billion compared to the $4.9 billion consensus, while Veklury projections come in at $141 million versus Street expectations of $216 million.
Gilead’s first-quarter earnings announcement is scheduled for April 23.
Analyst Community Remains Predominantly Positive
Several research firms maintain more optimistic positions. Cantor Fitzgerald reaffirmed its Overweight recommendation with a $155 valuation, highlighting robust prescription momentum throughout Gilead’s HIV product line.
UBS also sustained its Buy rating, noting a 56% sequential increase in Yeztugo sales during February. Deutsche Bank similarly maintained its Buy rating with a $155 target, forecasting first-quarter Yeztugo revenue of approximately $118 million.
In a separate development, Gilead has prolonged the acceptance period for its tender offer targeting Arcellx common shares until April 24, 2026. The proposal provides $115.00 per share in cash, supplemented by contingent value rights linked to future commercial performance milestones.
With first-quarter results approaching on April 23, investor focus will center on whether Yeztugo’s promising initial momentum delivers genuine revenue outperformance.
